MS016

MS016 is a monoclonal antibody currently in preclinical development by Medimscience for the treatment of inflammatory bowel disease (IBD). The drug specifically targets MT016, a proprietary macrophage-related protein, to modulate immune responses and alleviate chronic intestinal inflammation. By addressing macrophage-driven pathology, MS016 aims to provide a novel therapeutic approach for patients with Crohn's disease or ulcerative colitis. As a targeted immunotherapy, it is designed to reduce the inflammatory burden in the gastrointestinal tract while minimizing systemic side effects associated with broader immunosuppressants.